A Selective p38α Mitogen-Activated Protein Kinase Inhibitor Reverses Cartilage and Bone Destruction in Mice with Collagen-Induced Arthritis

Destruction of cartilage and bone is a poorly managed hallmark of human rheumatoid arthritis (RA). p38 Mitogen-activated protein kinase (MAPK) has been shown to regulate key proinflammatory pathways in RA, including tumor necrosis factor α, interleukin (IL)-1β, and cyclooxygenase-2, as well as the process of osteoclast differentiation. Therefore, we evaluated whether a p38α MAPK inhibitor, indole-5-carboxamide (SD-282), could modulate cartilage and bone destruction in a mouse model of RA induced with bovine type II collagen [collagen-induced arthritis (CIA)]. In mice with early disease, SD-282 treatment significantly improved clinical severity scores, reduced bone and cartilage loss, and reduced mRNA levels of proinflammatory genes in paw tissue, including IL-1β, IL-6, and cyclooxygenase-2. Notably, SD-282 treatment of mice with advanced disease resulted in significant improvement in clinical severity scoring and paw swelling, a reversal in bone and cartilage destruction as assessed by histology, bone volume fraction and thickness, and three-dimensional image analysis. These changes were accompanied by reduced osteoclast number and lowered levels of serum cartilage oligomeric matrix protein, a marker of cartilage breakdown. Thus, in a model of experimental arthritis associated with significant osteolysis, p38α MAPK inhibition not only attenuates disease progression but also reverses cartilage and bone destruction in mice with advanced CIA disease.

[1]  K. Vuolteenaho,et al.  Inhibitors of Mitogen-Activated Protein Kinases Downregulate COX-2 Expression in Human Chondrocytes , 2005, Mediators of inflammation.

[2]  G. Schreiner,et al.  p38α Mitogen-Activated Protein Kinase Inhibition Improves Cardiac Function and Reduces Myocardial Damage in Isoproterenol-Induced Acute Myocardial Injury in Rats , 2004, Journal of cardiovascular pharmacology.

[3]  I. Rioja,et al.  Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment , 2004, Clinical and experimental immunology.

[4]  S. Medicherla,et al.  Antinociceptive action of a p38α MAPK inhibitor, SD-282, in a diabetic neuropathy model , 2004, Pain.

[5]  Kwan Tat Steeve,et al.  IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004 .

[6]  S. Kwan Tat,et al.  IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004, Cytokine & growth factor reviews.

[7]  H. Genant,et al.  Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  N. Udagawa,et al.  p38 Mitogen-activated protein kinase is crucially involved in osteoclast differentiation but not in cytokine production, phagocytosis, or dendritic cell differentiation of bone marrow macrophages. , 2003, Endocrinology.

[9]  H. Yoshikawa,et al.  Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. , 2003, Arthritis and rheumatism.

[10]  Y. Kadono,et al.  Suppression of arthritic bone destruction by adenovirus-mediated dominant-negative Ras gene transfer to synoviocytes and osteoclasts. , 2003, Arthritis and rheumatism.

[11]  B. Månsson,et al.  Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept , 2003, Arthritis research & therapy.

[12]  U. Lerner,et al.  IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-κB Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Mouse Calvariae1 , 2002, The Journal of Immunology.

[13]  T. Nishihara,et al.  p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. , 2002, Endocrinology.

[14]  J. Reeve.  Recombinant human parathyroid hormone , 2002, BMJ : British Medical Journal.

[15]  Matthew J. Silva,et al.  SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts , 2002, Nature Network Boston.

[16]  John C. Lee,et al.  IL‐1‐ and TNF‐induced bone resorption is mediated by p38 mitogen activated protein kinase * , 2001, Journal of cellular physiology.

[17]  I. McLay,et al.  The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. , 2001, Bioorganic & medicinal chemistry.

[18]  H. Genant,et al.  Micro CT and Micro MR imaging of 3D architecture of animal skeleton. , 2000, Journal of musculoskeletal & neuronal interactions.

[19]  L. Joosten,et al.  IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. , 1999, Journal of immunology.

[20]  L. Joosten,et al.  Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis , 1999, Arthritis research.

[21]  H Perrier,et al.  Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. , 1999, The Journal of pharmacology and experimental therapeutics.

[22]  F. Berenbaum,et al.  Human chondrocyte culture models for studying cyclooxygenase expression and prostaglandin regulation of collagen gene expression. , 1999, Osteoarthritis and cartilage.

[23]  C. Manthey,et al.  Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. , 1999, Journal of immunology.

[24]  L. Joosten,et al.  IL-1αβ Blockade Prevents Cartilage and Bone Destruction in Murine Type II Collagen-Induced Arthritis, Whereas TNF-α Blockade Only Ameliorates Joint Inflammation , 1999, The Journal of Immunology.

[25]  H K Genant,et al.  Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. , 1998, Arthritis and rheumatism.

[26]  M. Feldmann,et al.  Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[27]  Y. Suzuki,et al.  Osteoclast-like cells in murine collagen induced arthritis. , 1998, The Journal of rheumatology.

[28]  A. Clerk,et al.  The p38‐MAPK inhibitor, SB203580, inhibits cardiac stress‐activated protein kinases/c‐Jun N‐terminal kinases (SAPKs/JNKs) , 1998, FEBS letters.

[29]  R. Holmdahl,et al.  Increased serum levels of cartilage oligomeric matrix protein in chronic erosive arthritis in rats , 1998, Arthritis and rheumatism.

[30]  L. Klareskog,et al.  Increased serum levels of cartilage oligomeric matrix protein and bone sialoprotein in rats with collagen arthritis. , 1997, British journal of rheumatology.

[31]  W. B. van den Berg,et al.  Dual role of IL-12 in early and late stages of murine collagen type II arthritis. , 1997, Journal of immunology.

[32]  J C Lee,et al.  Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. , 1997, Biochemical and biophysical research communications.

[33]  Philip R. Cohen,et al.  Activation of the novel stress‐activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases , 1997, The EMBO journal.

[34]  D E Griswold,et al.  Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. , 1996, The Journal of pharmacology and experimental therapeutics.

[35]  L. Joosten,et al.  Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. , 1996 .

[36]  John P. Bilezikian,et al.  Principles of Bone Biology , 1996 .

[37]  M. Helsen,et al.  Accelerated onset of collagen‐induced arthritis by remote inflammation , 1994, Clinical and experimental immunology.

[38]  P. Wooley,et al.  Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. , 1993, Journal of immunology.

[39]  M. Feldmann,et al.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Heinegård,et al.  Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. , 1992, British journal of rheumatology.

[41]  M. Cals,et al.  Effects of human recombinant IL-1 beta on rheumatoid and non rheumatoid human synovial cell growth. , 1990, Cellular and molecular biology.

[42]  R. Recker,et al.  Bone histomorphometry : techniques and interpretation , 1983 .